Abstract
AbstractChinese herbal medicines (CHMs) have unique advantages in the prevention and treatment of diseases, which are widely recognized in the world. More and more CHMs are becoming increasingly popular in the international markets. However, the quality control of CHMs is a significant issue for their acceptance and recognition in the international market. This review mainly focuses on the quality requirements for CHMs to enter the European Union (EU) market. Both Chinese and European regulations and quality controls are compared. Firstly, the EU medicinal regulatory system and relevant regulations were reviewed. Secondly, the key factors of the quality control of CHMs, including Chinese herbal drugs, extracts and products were compared with those of European herbal medicines in the EU market. Subsequently, three main registration routes for herbal medicinal products including Chinese herbal medicinal products entering the EU were introduced. Furthermore, the legal status of traditional Chinese medicine granules in the EU was also discussed. Through the comparison of the key quality factors for CHMs in China and the EU, the similarities and differences in terms of quality requirements and regulations are addressed, which provides a reference for the development of CHMs into the EU market.
Funder
The Science and Technology Development Fund, Macau SAR
National Natural Science Foundation of China
Universidade de Macau
Guangxi Science and Technology Research Project
Dutch Provincie Noord_Holland MIT grant
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference39 articles.
1. Matos LC, Machado JP, Monteiro FJ, Greten HJ. Understanding traditional Chinese medicine therapeutics: an overview of the basics and clinical applications. Healthcare. 2021;9:257.
2. Wu X, Wang SP, Lu JR, Jing Y, Li MX, Cao JL, et al. Seeing the unseen of Chinese herbal medicine processing (Paozhi): advances in new perspectives. Chin Med. 2018;13:4.
3. Zhao ZZ, Liang ZT, Chan K, Lu GH, Lee ELM, Chen HB, et al. A unique issue in the standardization of Chinese materia medica: processing. Planta Med. 2010;76:1975–86.
4. Wang M, Franz G. The role of the European Pharmacopoeia (Ph Eur) in Quality Control of Traditional Chinese Herbal Medicine in European Member States. World J Tradit Chin Med. 2015;1:5–15.
5. Duan DX, Zhou SY, Chen Y, Huang C, Li Y. Analysis of formulation and application of the common traditional Chinese medicine. Asia-Pacific Tradit Med. 2017;1:66–8.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献